The health technology assessment body NICE is to look again at its decision not to recommend National Health Service funding in England for Clinuvel Pharmaceuticals Ltd.’s phototoxicity drug Scenesse, after an appeals panel upheld several objections by the company and patient organizations to NICE’s conclusions.
The panel said that NICE’s Highly Specialized Technologies committee would need to address a number of issues regarding the way...








